News & Events
News & Events
Institut Pasteur Korea and Korea Research Institute for Bioscience & Biotechnology sign agreement to cooperate to the benefit of research on infectious disease
2018-12-04
Daejeon, Rep. of Korea, December 04th, 2018 Institut Pasteur Korea (IPK) signed a memorandum of understanding (MOU) with the Korea Research Institute for Bioscience & Biotechnology (KRIBB) for research cooperation in the field of infectious disease research. “Working together KRIBB and IPK can share their world-class knowledge and resources for development of new medicine, therapies, and diagnostics to combat infectious diseases” said Dr. Wang-Shick Ryu, CEO of IPK. The KRIBB President Jang-Seong Kim added: “The partnership with IPK on infectious disease will exploit scientific and technological complementarities, and is expected to have broad impact on the diverse research portfolio of KRIBB, and the drug discovery output of IPK”.
.jpg)
Photo: (left) KRIBB President Jang-Seong Kim, and Pr. Wangshick Ryu (CEO IPK); (right) scientists from IPK and IPP join in celebration of the MOU signing.
Infectious disease outbreak and spread represents a threat to public health in Korea and worldwide, highlighted by challenges such as the emergence of antibiotic and antimicrobial resistance; global outbreak and rapid transmission of infectious disease such as the Korean peninsula’s 2015 MERS outbreak. Middle East respiratory syndrome (MERS) is a highly fatal respiratory disease caused by a novel coronavirus (MERS-CoV). From May to July 2015, the Republic of Korea experienced the largest ever outbreak of MERS to occur outside the Arabian Peninsula. It took 8 weeks for transmission to abate.
“Cooperation between KRIBB and IPK will provide an advantage to help leverage studies aimed to combat pathogens important to the Korean Public Health space such as MERS, hepatitis, tuberculosis, and antibiotic resistant bacteria found in hospitals and communal spaces” said President Jong-Seong Kim. “Such initiative will increase preparedness for such outbreaks in the future, that will make all the difference to risk management, and ultimately saving lives” said Dr Ryu.
KRIBB Vice-President Seung-Jun Kim, and Dr. Spencer Shorte, CSO of IPK together agreed: “It is our wish that the IPK/KRIBB MOU will benefit globally to enhance Korea’s biomedical research landscape, highlighting the value of biotechnology and bioresource innovation as central to combatting infectious diseases like MERS.”
“Working hand-in-hand with other key Korean research institutes we will be able to better leverage our world-leading Korean and international scientists, with cutting-edge technologies for accelerated development of new, cost-effective drug treatments and therapies to treat infectious diesases threatening public health at domestic and global scales.”
# # # # # #
About Institut Pasteur Korea
The Institut Pasteur Korea(IPK) is an international research institute with a basic research mission for infectious disease, and drug development to the benefit of public health. The institute was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology(KIST), and is grateful for continous support from the Ministry of Science and ICT(MSIT), and the Gyeonggi Provincial govenment.
About Korea Institute for Biotechnology and Bioresources
The Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation. KRIBB was established in 1985.
Photo: (left) KRIBB President Jang-Seong Kim, and Pr. Wangshick Ryu (CEO IPK); (right) scientists from IPK and IPP join in celebration of the MOU signing.
Infectious disease outbreak and spread represents a threat to public health in Korea and worldwide, highlighted by challenges such as the emergence of antibiotic and antimicrobial resistance; global outbreak and rapid transmission of infectious disease such as the Korean peninsula’s 2015 MERS outbreak. Middle East respiratory syndrome (MERS) is a highly fatal respiratory disease caused by a novel coronavirus (MERS-CoV). From May to July 2015, the Republic of Korea experienced the largest ever outbreak of MERS to occur outside the Arabian Peninsula. It took 8 weeks for transmission to abate.
“Cooperation between KRIBB and IPK will provide an advantage to help leverage studies aimed to combat pathogens important to the Korean Public Health space such as MERS, hepatitis, tuberculosis, and antibiotic resistant bacteria found in hospitals and communal spaces” said President Jong-Seong Kim. “Such initiative will increase preparedness for such outbreaks in the future, that will make all the difference to risk management, and ultimately saving lives” said Dr Ryu.
KRIBB Vice-President Seung-Jun Kim, and Dr. Spencer Shorte, CSO of IPK together agreed: “It is our wish that the IPK/KRIBB MOU will benefit globally to enhance Korea’s biomedical research landscape, highlighting the value of biotechnology and bioresource innovation as central to combatting infectious diseases like MERS.”
“Working hand-in-hand with other key Korean research institutes we will be able to better leverage our world-leading Korean and international scientists, with cutting-edge technologies for accelerated development of new, cost-effective drug treatments and therapies to treat infectious diesases threatening public health at domestic and global scales.”
# # # # # #
About Institut Pasteur Korea
The Institut Pasteur Korea(IPK) is an international research institute with a basic research mission for infectious disease, and drug development to the benefit of public health. The institute was established in April 2004 in collaboration with Institut Pasteur Paris and the Korea Institute of Science and Technology(KIST), and is grateful for continous support from the Ministry of Science and ICT(MSIT), and the Gyeonggi Provincial govenment.
About Korea Institute for Biotechnology and Bioresources
The Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation. KRIBB was established in 1985.